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ment as well as anginal pains. Rate of arrhythmia at discharge
was minimal in streptokinase group. Alteplase required much
more costs than streptokinase or treatment without thrombolyt-
ical therapy. ICER was 252,454.31 rubles ($7889.20) per
absence of heart failure at discharge for alteplase vs streptoki-
nase, and 166,720.5 rubles ($5210.02) for alteplase vs treatment
without thrombolytical therapy. Still streptokinase was more
cost-effective vs treatment without thrombolytical therapy: ICER
was 4038.76 rubles ($126.21) per absence of heart failure at dis-
charge. CONCLUSION: Alteplase is less cost-effective throm-
bolytical strategy for MI than streptokinase in spite of higher
effectiveness.
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OBJECTIVES: We assessed the long-term cost-effectiveness of
the use of clopidogrel on top of standard therapy (including
aspirin) in comparison with ASA only in patients undergoing
percutaneous coronary interventions in Sweden. METHODS: A
Markov model was developed. Transition probabilities for rele-
vant events were estimated based on RIKS-HIA, a register on
patients treated in the coronary care units at 74 (out of 78) hos-
pitals throughout Sweden. Patients were assumed to be treated
for one year with an effect based on the PCI-CURE trial. Costs
for the intervention and the deﬁned events were collected from
published sources and recalculated to 2003 prices. Life-years
gained were used as the measure of effectiveness, with QALYs
gained as a sensitivity analysis. The perspective was that of the
Swedish society with a separate analysis using a health care cost
perspective. Costs and effects were discounted at 3%. RESULTS:
The model predicts a net gain in survival of 0.04 years when
adding clopidogrel. This comes at a net increased cost of 441€
if only direct costs are included. Including indirect costs, the net
increase is reduced to 326€. The resulting cost-effectiveness ratio
was 10,782€ and 7971€ per life-year gained for the different def-
initions of cost. Assuming a 0.1 reduction in utility following a
MI, the cost per QALY gained was 6381€. Cost-effectiveness
ratios were even lower in diabetics compared to non-diabetics.
Results were robust to changes in discount rate and variations
in unit costs. CONCLUSIONS: The predicted cost-effectiveness
ratios are well below the threshold values generally considered
cost-effective. Adding clopidogrel to ASA thus appears cost-
effective in this indication.
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OBJECTIVES: High density lipoprotein-cholesterol (HDL-C) is
inversely and independently associated with increased risk of car-
diovascular disease (CVD). The importance of HDL-C as a risk
factor for CVD is well accepted. We performed a modelling study
to estimate the incremental cost per additional patient achieving
target HDL-C (≥1mmol/L) when Niaspan (extended release
niacin) is added to stable statin therapy in CVD patients from
the perspective of the National Health Service in the UK.
METHODS: A 3-step probabilistic model was developed. Step
1: population of 10,000 patients with a normal distribution of
lipid proﬁles deﬁned by mean and standard deviation was
created. Step 2: treatment effects of atorvastatin 10mg were
applied to the population and those whose low density lipopro-
tein-cholesterol (LDL-C) was satisfactory (£3.0mmol/L) but did
not reach target HDL-C (≥1.0mmol/L) received treatment with
Niaspan. Step 3: treatment effects of Niaspan were applied in
patients. Baseline lipid values and treatment effects were ran-
domly sampled from distributions drawn from published epi-
demiological and clinical studies using second order Monte
Carlo methodology. Cost for drugs and initiation of Niaspan
treatment were taken from published sources. Results were pre-
sented for the initiation year, taking into account initiation costs
and drop-outs, and maintenance year scenarios. RESULTS: In
total, 16.3% of patients required Niaspan in addition to ator-
vastatin treatment to control dyslipidemia. Of these patients,
29.4% and 36.7% reached target HDL-C after addition of
Niaspan in the initiation and maintenance years respectively.
Additional costs in Niaspan treated patients were £320.30 
and £252.30 for initiation and maintenance years respectively,
leading to incremental costs of £1089 and £687 per additional
patient achieving HDL-C target. CONCLUSIONS: The addi-
tional costs per patient treated to HDL-C target by adding
Niaspan to statin therapy are comparable to those reported in
the literature for treating patients with statins to LDL-C or total
cholesterol targets.
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OBJECTIVES: Little is known about the cost-effectiveness of
secondary prevention after percutaneous coronary intervention
(PCI). Aims of this study are to estimate 1) the cost-effectiveness
of routine ﬂuvastatin therapy after a ﬁrst successful PCI in The
Netherlands, and 2) the chance that ﬂuvastatin therapy is cost-
effective given a society’s willingness to pay as laid down in
Dutch guidelines. METHODS: A cost-effectiveness analysis was
performed using data from the Lescol Intervention Prevention
Study (LIPS). In the LIPS trial, patients with normal blood cho-
lesterol to moderate hypercholesterolemia who had undergone a
ﬁrst PCI were randomized to receive either ﬂuvastatin 40mg
twice-daily plus dietary counseling or dietary counseling alone.
A Markov model (DataPro) was used to estimate the incremen-
tal costs per quality-adjusted life year (QALY) and life year
gained (LYG). Costs were based on prices and reimbursed
charges, utility data were drawn from literature. Hospital costs
(admissions and procedures) were extracted from a database
with complete national coverage. 10,000 Monte Carlo simula-
tions and multivariate analysis were used to assess (2nd order)
uncertainty. RESULTS: The mean net incremental costs of
routine statin treatment were 734€ (SD: 686€) per patient over
10-years compared with controls. Treatment resulted in an incre-
mental 0.078 (0.047) QALYs or 0.082 LYG (0.041). The incre-
mental cost per QALY and LYG were 9312€ (14,648€) and
8954€ (16,617€) respectively. The sensitivity analysis revealed
that the cost of ﬂuvastatin and the discount rate had the largest
effect on the ICER. Anticipating a willingness to pay of 20,000€
per QALY, there is a 75.1% chance that ﬂuvastatin treatment is
cost-effective. CONCLUSIONS: Statin therapy with ﬂuvastatin
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is economically efﬁcient with regard to reducing heart disease in
The Netherlands when given routinely to all patients following
PCI.
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OBJECTIVE: To assess cost-effectiveness of ezetimibe 10mg
(EZ10) co-administration with simvastatin versus a simvastatin
dose titration strategy in CHD patients who do not attain cho-
lesterol goal (TC < 5mmol/L) with simvastatin monotherapy.
METHOD: A decision-analytic model was developed to project
lifetime costs and beneﬁts of lipid therapy. Clinical trial data
were used to estimate TC reductions for different treatment
strategies. The effect of TC reductions on CHD event rates was
estimated using Framingham equations and Hungarian National
Statistics data on nonCHD-related mortality. Direct costs of
CHD events in Hungary, Hungarian prices for simvastatin and
EZ 10 price (based on German EZ10 price) were used to project
lifetime costs. The model was run for a population consisting of
138 CHD patients who are currently treated with simvastatin in
an observational Lipid Lowering Treatment study conducted in
Hungary, and had not reached goal at the TC measurement after
minimum 60 days of treatment. RESULTS: For these patients
(mean age 62.9 years, 51% male, lipid proﬁle on simvastatin
LDL-C 3.55mmol/l, TC 5.99mmol/l, HDL 1.44mmol/l, triglyc-
erides 2.40mmol/l), EZ10 co-administered with simvastatin
compared to simvastatin titration is projected to increase life
expectancy by 0.69 years with a discounted C/LY of 14,891€ and
the discounted C/QALY’s of 14,827€. CONCLUSIONS: Treat-
ment with EZ10 co-administered with simvastatin for CHD
patients not at goal is projected to be a more cost-effective alter-
native to simvastatin titration which is substantially under the
limit C/LY of 30,000€.
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OBJECTIVES: Numerous clinical studies have demonstrated the
safety and effectiveness of radiofrequency catheter ablation for
treatment of ventricular tachycardia (VT). The objective was to
evaluate the cost effectiveness of catheter ablation relative to
drug therapy to treat frequent recurrence of VT among patients
with structural heart disease. METHODS: We calculated the
incremental cost effectiveness of catheter ablation relative to
daily amiodarone treatment over various time horizons up to 5
years using a decision analytic Markov model (DATA 4.0TM,
TreeAge Software Inc.). Costs were based on a third party payer’s
perspective using 2004 Medicare reimbursement schedules and
discounted average wholesale drug prices. Model parameters,
adverse event rates, and utility weight estimates were obtained
from randomized clinical trial literature and expert opinion.
Costs and effects were discounted at 3% annually and sensitiv-
ity analyses were performed. The model analyzed the outcomes
and resource utilization of a hypothetical cohort of 10,000
patients with structural heart disease and implantable car-
dioverter-deﬁbrillators who experience frequent VT episodes.
RESULTS: Ablation consistently produced greater quality
adjusted life years (QALYs) compared to amiodarone in analy-
ses of 1 to 5 years. The incremental QALYs of ablation relative
to amiodarone at 1,2 and 3-years are 0.477, 0.82 and 1.05. The
average 1, 2, and 3-year costs for ablation ($14,000, $14,760,
$15,330) are higher compared to amiodarone ($10,760,
$12,870, $14,760). However, over a 5-year time horizon, the
average cost of ablation is less than amiodarone. The incremen-
tal cost-effectiveness ratio of ablation relative to amiodarone
decreases from $81,340 at 1 year to $6392 at 3 years. By 3.6
years, ablation dominates amiodarone. CONCLUSIONS:
Catheter ablation treatment of VT becomes increasingly cost
effective compared to drug therapy as the time horizon increases
and after 3.6 years, ablation is less costly and more effective than
amiodarone therapy.
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OBJECTIVES: LIFE was a double-masked, randomized trial of
losartan vs. atenolol in 9193 patients with essential hypertension
and LVH ascertained by electrocardiography. Losartan reduced
the primary composite endpoint of cardiovascular death,
myocardial infarction, or stroke by 13% (p = 0.021) and reduced
the risk of stroke by 25% (p = 0.001), despite a similar degree
of blood pressure control. Our objective was to assess the cost-
effectiveness of losartan compared with atenolol in hypertensive
patients with LVH, from the perspective of the Spanish Health
Care system. METHODS: Losartan and atenolol utilisation
within the trial period and lifetime direct medical costs follow-
ing a stroke in Spain were combined with estimates of reduction
in life expectancy following stroke. The cumulative incidence of
stroke and study medication utilization after 5.5 years of patient
follow-up were separately estimated, adjusting for baseline
degree of LVH and Framingham risk score. To estimate per
patient lifetime stroke costs, we multiplied the cumulative inci-
dence of stroke by the lifetime direct medical cost attributable to
stroke. All costs and beneﬁts are in 2004 Spanish prices dis-
counted at 3% annually. RESULTS: Losartan reduced stroke-
related cost by 270€ per patient due to a lower cumulative
incidence of stroke at 5.5 years (4.9% vs. 6.5%; p = 0.003). Net
costs were 1626€ higher per patient over 5.5 years for losartan
compared with atenolol. The number of life-years gained (LYG)
by preventing a stroke was 5.6 years, resulting in 0.090 (dis-
counted) LYG per patient with losartan. The estimated cost per
LYG for losartan was 18,147€ (95% CI: 10,127, 46,724) which
is well within bench-mark values (30,000€/LYG) for accepted
cost effective interventions in Spain. The probability of the cost-
effectiveness ratio falling below a threshold of 30,000€/LYG was
0.88. CONCLUSIONS: Treatment with losartan compared with
atenolol over a 5.5 year period is, based on the cost per LYG, a
cost-effective intervention in Spain.
